Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17039437 | 0.78 | MAPT (0.42) | ALDH1A1MAPTTSHRHPGD | |
| SCHEMBL17039355 | 0.76 | TSHR (0.43) | ALDH1A1MAPTTSHRHPGDPOLB | |
| SCHEMBL12449176 | 0.75 | ALDH1A1 (0.46) | ALDH1A1MAPTTSHRPOLBNPSR1 | |
| SCHEMBL17039349 | 0.74 | ALDH1A1 (0.44) | ALDH1A1MAPTTSHRHPGDNPSR1 | |
| SCHEMBL12448159 | 0.74 | ALDH1A1 (0.46) | ALDH1A1MAPTTSHRHPGDL3MBTL1 | |
| SCHEMBL105392 | 0.74 | POLB (0.39) | ALDH1A1MAPTTSHRHPGDPOLB | |
| SCHEMBL17036734 | 0.73 | ALDH1A1 (0.34) | ALDH1A1TSHRHPGDPOLBL3MBTL1 | |
| SCHEMBL17036719 | 0.72 | TSHR (0.36) | ALDH1A1MAPTTSHRHPGDPOLB | |
| SCHEMBL17574701 | 0.71 | POLB (0.37) | ALDH1A1MAPTTSHRHPGDPOLB | |
| SCHEMBL178417 | 0.70 | L3MBTL1 (0.49) | ALDH1A1MAPTTSHRL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022766-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022766-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | TFPI, CFD, C9 | ALDH1A1 2728/4885MAPT 3823/4885TSHR 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.